Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

(2016) Jung Soo Suk et al.   ADVANCED DRUG DELIVERY REVIEWS

Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs

(2016) Y. Schilt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

(2016) Alberto A. Gabizon et al.   DRUG RESISTANCE UPDATES

A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data

(2016) Masahiko Nakayama et al.   GYNECOLOGIC ONCOLOGY

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin

(2016) Grant H. Petersen et al.   JOURNAL OF CONTROLLED RELEASE

Pegylated liposomal doxorubicin in the management of ovarian cancer

(2016) Gabriella Ferrandina   Therapeutics and Clinical Risk Management

Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

(2015) Hiroshi Maeda   ADVANCED DRUG DELIVERY REVIEWS

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters

(2015) Zahra Ajgal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)

(2015) C.L. Kushnir et al.   GYNECOLOGIC ONCOLOGY

In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site

(2015) Lisa Silverman et al.   Nanomedicine-Nanotechnology Biology and Medicine

Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

(2014) Marye J. Boers-Sonderen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin

(2014) Takuya Suzuki et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients

(2013) Emily M. Ko et al.   GYNECOLOGIC ONCOLOGY

Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin

(2013) Noriyuki Yokomichi et al.   Human Cell

First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial

(2012) Ó Arrieta et al.   BRITISH JOURNAL OF CANCER

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

Pegylated Liposomal Doxorubicin

(2011) Sean T. Duggan et al.   DRUGS

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

(2011) Alberto Gabizon et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment

(2011) Matteo Morotti et al.   Expert Opinion on Drug Metabolism & Toxicology

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

(2011) Florence Joly et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer

(2010) Hans-Georg Strauss et al.   ANTI-CANCER DRUGS

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients

(2010) Vivian von Gruenigen et al.   CANCER

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY

Prevention strategies in palmar–plantar erythrodysesthesia onset: The role of regional cooling

(2008) G. Mangili et al.   GYNECOLOGIC ONCOLOGY

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)

(2007) David S. Alberts et al.   GYNECOLOGIC ONCOLOGY